Rituximab's property of depleting CD20-positive B cells while sparing stem and plasma cells has been used successfully in the treatment of non-Hodgkin's lymphoma (NHL) [22] and in autoimmune disorders such as RA, SLE, and IgM-mediated neuropathies [23-27]. Here, CD40LG is linked to neuropathy.